Skip to content
Search Join us
  1. Home
  2. Resources
  3. Consultation responses

Response to MHRA’s consultation on the availability of diclofenac as a pharmacy medicine

 

 

MHRA (Medicines and Healthcare Products Regulatory Agency) ran a consultation on the continued availability of diclofenac as a Pharmacy (P) medicine and on the risk minimisation measures advised by the Commission on Human Medicines.

The Society recommended that diclofenac tablets be reclassified to a prescription only medicine.

Stay up to date

Subscribe to our newsletter for updates on meetings & events, editor's picks and journal news, career opportunities and training & workshop announcements. 

Subscribe to our newsletter

Latest consultation responses

The Good Clinical Trials Collaborative published new draft guidance for Randomized Controlled Trials (RCT). This guidance was developed in partnership…

 

 

In June 2021, the Department of Health & Social Care opened a call for evidence to inform their Women’s Health Strategy. In the…

 

 

The Nuffield Council on Bioethics recently launched a new in-depth project on the future of ageing. Within this, was a consultation…

Cookie Extension Logo